Explore alternatives for weight loss amidst the Wegovy shortage. Learn about effective options to achieve your weight loss goals on Aktwisted Wellness.
WHAT IS WEGOVY?
Wegovy (semaglutide) is a prescription injectable medication known for its effectiveness in weight loss. Acting as a GLP-1 receptor agonist, Wegovy regulates appetite and blood sugar levels, aiding in weight loss by signaling fullness and delaying stomach emptying.
IS THERE A WEGOVY SHORTAGE?
Yes, a shortage of Wegovy is anticipated to continue until at least September 2023 due to high demand. While the shortage affects lower dosage strengths, individuals on higher strengths may face fewer challenges obtaining their prescription.
WEGOVY ALTERNATIVES
Explore alternative weight loss medications if Wegovy is inaccessible:
- Saxenda (liraglutide): A daily injection similar to Wegovy, Saxenda promotes weight loss with fewer side effects.
- Other GLP-1 medications: Options like Ozempic, Mounjaro, Trulicity, and Tanzeum offer weight loss benefits and may be prescribed off-label.
- Qsymia (phentermine/topiramate): Stimulates weight loss when combined with a low-calorie diet and exercise.
- Contrave (naltrexone/bupropion): An oral weight loss pill with potential side effects like nausea and insomnia.
- Xenical (orlistat): Reduces fat absorption, aiding in weight loss with gastrointestinal side effects.
CONCLUSION
Despite the Wegovy shortage, individuals have viable alternatives for weight loss. Consult your healthcare provider to find the best option for you.
DISCLAIMER
Consult your healthcare provider for personalized advice. Information in this article is based on peer-reviewed research and should not substitute professional medical guidance.
SOURCES:
- FDA. (2021). FDA approves new drug for chronic weight management, first since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management-first-2014
- Novo Nordisk. (2023). Novo Nordisk provides update on the supply situation for Wegovy®. https://www.novonordisk.com/about-novo-nordisk/novo-nordisk-news-and-media/news-display-uk-153836.html
- FDA. (2020). Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communication-completed-safety-review-xenicalalli-orlistat-and-severe-liver-injury
- Astrup, A., et al. (2017). Obesity management with liraglutide 3.0 mg versus placebo in combination with diet and physical activity: The SCALE obesity and prediabetes randomized trial. https://pubmed.ncbi.nlm.nih.gov/28028947/
- Apovian, C. M., et al. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). https://pubmed.ncbi.nlm.nih.gov/23544092/